RE: Strong H1 and Q228 Jul 2022 09:55
ndivior, which makes drugs to treat opioid addiction, said it plans to seek an additional listing in the US. It will ask for shareholder approval in September for a listing to take place in the spring of next year. "The group believes an additional US listing will be beneficial in elevating Indivior's visibility and profile in its largest market, and in potentially attracting a broader group of biopharma investors," it said. The plan, first revealed back in March, was discussed as part of Indivior's half-year results. Pretax profit slipped to USD106 million in the first half of 2022 from USD119 million a year before, even as net revenue rose by 12% to USD428 million from USD381 million.